Patient demographics and disease characteristics
| Variables . | n (%)/median (range) . |
|---|---|
| Age (median, range), y | 64 (20-92) |
| Age ≤60 y | 58 (38.9) |
| Sex, male | 88 (59.1) |
| Time from diagnosis to vaccination, mo | 22 (0.2-354) |
| Diagnosis | |
| a-B-NHL | 69 (47) |
| i-B -NHL | 80 (53) |
| ALC (×103/μL) mean ± standard deviation, median (range) | 1.7 ± 2.9, 1.08 (0.26-30.5) |
| Treatment status | |
| Treatment naïve (watch and wait) | 28 (18.8) |
| Actively treated (≤6 mo from last anti-CD20 therapy) | 55 (37) |
| Completed treatment >6 mo | 66 (44.2) |
| Any exposure to anti-CD20 Abs | 121 (81.2) |
| Median time (mo) from last anti-CD20 Ab therapy (range) | 7.3 (0-204) |
| Disease status (for 111 evaluable patients of 121 treated patients) | |
| CR | 98 (88.3) |
| PR | 6 (5.4) |
| SD | 3 (2.7) |
| PD | 4 (3.6) |
| Variables . | n (%)/median (range) . |
|---|---|
| Age (median, range), y | 64 (20-92) |
| Age ≤60 y | 58 (38.9) |
| Sex, male | 88 (59.1) |
| Time from diagnosis to vaccination, mo | 22 (0.2-354) |
| Diagnosis | |
| a-B-NHL | 69 (47) |
| i-B -NHL | 80 (53) |
| ALC (×103/μL) mean ± standard deviation, median (range) | 1.7 ± 2.9, 1.08 (0.26-30.5) |
| Treatment status | |
| Treatment naïve (watch and wait) | 28 (18.8) |
| Actively treated (≤6 mo from last anti-CD20 therapy) | 55 (37) |
| Completed treatment >6 mo | 66 (44.2) |
| Any exposure to anti-CD20 Abs | 121 (81.2) |
| Median time (mo) from last anti-CD20 Ab therapy (range) | 7.3 (0-204) |
| Disease status (for 111 evaluable patients of 121 treated patients) | |
| CR | 98 (88.3) |
| PR | 6 (5.4) |
| SD | 3 (2.7) |
| PD | 4 (3.6) |
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.